Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Phase III study of sildenafil in newborns with PPHN does not meet primary efficacy endpoint

July 1, 2019

Bayer initiates phase II AVANTI study of BAY-1753011 in congestive heart failure

July 1, 2019

BR-11257, a novel nonstabilizing soluble guanylyl cyclase partial agonist

July 1, 2019

CD28 unveiled as potential therapeutic target for giant-cell arteritis

June 28, 2019

Arena Pharmaceuticals divulges beta3-adrenoceptor antagonists

June 28, 2019

Metabolic enzyme targeting takes on pulmonary hypertension

June 28, 2019

BIAL-Portela discloses DBH inhibitors

June 27, 2019

Faron reports interim data from phase II INFORAAA study of Traumakine

June 26, 2019

Dosing starts in phase I study of gene therapy to treat Danon disease

June 19, 2019

Pharvaris describes bradykinin B2 receptor antagonists

June 13, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...